Skip to main content

09-22-2017 | Insulin glargine | EASD 2017 | News

News in brief

Higher dose of insulin glargine supported for type 2 diabetes

medwireNews: Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

Boris Kovatchev, from the University of Virginia in Charlottesville, USA, and colleagues analyzed daily self-monitored blood glucose profiles among 2649 type 2 diabetes patients who were treated with insulin glargine in the EDITION 2, EDITION 3, or Senior Study clinical trials.

There was a “consistently lower risk” in the incidence and frequency of hypoglycemia among participants who received the higher dose, and this difference was “most evident during the night time period,” Kovatchev told delegates at the EASD annual meeting in Lisbon, Portugal.

Furthermore, the team showed that the Low Blood Glucose Index (LBGI) – a specific measure of glucose variability – could be used to predict hypoglycemia risk, with participants who had an LBGI score above 1.1 points having significantly more documented hypoglycemic episodes than those with lower scores.

“We were able to identify the people who are at risk for hypoglycemia by quantifying a simple metric out of their self-monitoring profiles,” said Kovatchev.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See also:

Related topics

CME-accredited GLP-1RAs webcast

Learn more about GLP-1RAs with John Wilding, Julie Lovshin and Kamlesh Khunti

CME-accredited GLP-1RAs webcast on real-world data

Led by Melanie Davies, Stewart Harris & Takashi Kadowaki, this on-demand webcast focuses on treatment with GLP-1RAs, based on real-world data, and the emerging landscape of GLP-1RAs in the context of approved guidelines.

Image Credits